Loading...
XTAI
4133
Market cap42mUSD
Oct 08, Last price  
22.65TWD
1D
4.38%
1Q
8.89%
Jan 2017
-36.52%
IPO
-79.63%
Name

Abnova Taiwan Corp

Chart & performance

D1W1MN
XTAI:4133 chart
P/E
—
P/S
3.90
EPS
—
Div yield, %
3.97%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-5.10%
Revenues
351m
-1.11%
402,834,000475,072,000472,569,000463,774,000463,699,000438,112,000451,367,000439,826,000475,073,000426,023,000414,158,000456,449,000451,487,000411,756,000382,052,000355,257,000351,299,000
Net income
-1m
L
99,558,000149,045,000119,865,00076,838,00072,896,00065,643,00044,911,00053,539,00058,966,00046,118,0003,263,00036,526,00028,369,00074,843,00043,678,00061,607,000-1,141,000
CFO
-4m
L
63,721,000114,400,000134,225,00076,021,000109,778,00094,180,00073,428,00071,936,00067,529,00089,168,00074,513,000105,300,00092,875,000132,369,00076,219,00050,852,000-4,192,000
Dividend
Jun 16, 20260.112 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.

Key people

Peiru Ji
General Manager · since 2023
Yiling Dong
Corporate Governance Officer · since 2023
Yaping Zhang
Head of Finance & Accounting · since 2019
Yuehong Chen
Director · since 2020
Wilber Huang
Chairman of the Board · since 2023
Fangwen Li
Director · since 2020
Qijing Qiu
Director · since 2012
Anna Cha
Independent Director · since 2025
Jiaxun Lin
Independent Director · since 2017
Jinjun Su
Independent Director · since 2017
Independent Director · since 2017
IPO date
May 27, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT